Guardion Health Sciences FY2023 revenue up 10.8% to $12.2M; selling main asset and planning dissolution

Guardion Health Sciences, Inc.

2024-Q1 EPS reported -$3.71 revenue$2,999,645

FY2023 revenue $12.2M (+10.8% YoY); net income $0.2M vs $(14.9M) loss prior year; EPS $0.12.
Viactiv product line generated $11.9M (+11.9% YoY), representing 97.2% of total revenue.
On Jan 30, 2024, agreed to sell Activ Nutritional (owner of Viactiv) for $17.2M cash, subject to stockholder approval.
Board proposes voluntary dissolution and liquidation after sale closes; special meeting set for May 23, 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Guardion Health Sciences, Inc. reported the year ended December 31, 2023 results: revenue $12,248,550, net income $158,033, EPS $0.12.

Period: the year ended December 31, 2023
Revenue: $12,248,550
Net income: $158,033
EPS: $0.12
Result: reported results

Exact text from the filing

31, 2023. The Company also provided a corporate update to stockholders. Financial highlights for the year ended December 31, 2023 include the following: ● Total revenue was $12,248,550 for the year ended December 31, 2023, as compared to $11,049,772 for the year ended December 31, 2022, an increase of $1,198,778, or 10.8%. The Viactiv ® product line generated

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001493152-24-012133

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.